Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.53 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081960 | 0.96 | GRM2 (0.55) | GRM2TACR2TACR1FAAHHRH3 | |
| SCHEMBL3073111 | 0.90 | GRM2 (0.50) | GRM2TACR2TACR1FAAHHRH3 | |
| SCHEMBL3077062 | 0.90 | GRM2 (0.44) | GRM2TACR2TACR1HRH3HCRTR1 | |
| SCHEMBL3062958 | 0.86 | GRM2 (0.54) | GRM2 | |
| SCHEMBL13140370 | 0.85 | GRM2 (0.51) | GRM2TACR2TACR1HSD11B1L3MBTL1 | |
| SCHEMBL3068864 | 0.82 | GRM2 (0.58) | GRM2FAAHMCHR1MGLL | |
| SCHEMBL8208252 | 0.82 | GRM2 (0.49) | GRM2TACR2TACR1HRH3 | |
| SCHEMBL3074732 | 0.82 | GRM2 (0.49) | GRM2TACR2TACR1HSD11B1 | |
| SCHEMBL3077894 | 0.81 | GRM2 (0.50) | GRM2HRH3HSD11B1 | |
| SCHEMBL3057908 | 0.80 | GRM2 (0.53) | GRM2TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790717-B2 | administering 3-(4'-Morpholin-4-ylmethyl-biphenyl-4-ylmethyl)-1-oxa-3-aza-spiro[4.5]decan-2-one, for the treatment of schizophrenia | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | claimed |
| EP-2061775-A2 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | Astra Zeneca AB (SE) | 2009-05-27 | — | — | EP | claimed |
| US-20090124578-A1 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | claimed |
| US-7485722-B2 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | claimed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | claimed |
| WO-2008032191-A2 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (US) | 2008-03-20 | — | — | WO | claimed |
| US-8735397-B2 | Method for treating schizophrenia and related diseases | VANDERBILT UNIVERSITY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735397-B2 | Method for treating schizophrenia and related diseases | VANDERBILT UNIVERSITY (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735397-B2 | Method for treating schizophrenia and related diseases | VANDERBILT UNIVERSITY (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2011122701-A1 | METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES | VANDERBILT UNIVERSITY (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110237602-A1 | METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES | VANDERBILT UNIVERSITY (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237602-A1 | METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES | VANDERBILT UNIVERSITY (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237602-A1 | METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES | VANDERBILT UNIVERSITY (US) | 2011-09-29 | — | — | US | disclosed |
| US-7485722-B2 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-7485722-B2 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-7485722-B2 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| WO-2008032191-A2 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124578-A1 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | GRM1, GRIN1, GRM2 | GRM2 3/4885TACR2 167/4885TACR1 121/4885 |
| US-20110237602-A1 | METHOD FOR TREATING SCHIZOPHRENIA AND RELATED DISEASES | GRM2, GRIA2, GRIK2 | GRM2 1/4885TACR2 90/4885TACR1 163/4885 |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885TACR2 167/4885TACR1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.